The Journal of Liquid Biopsy最新文献

{"title":"Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India.","authors":"Pradnya Joshi, Prachi Gogte, Prachi Pawar, Mamta Gurav, Ramya Iyer, Shambhavi Singh, Sonam Hatkar, Ujwal Shetty, Aruna Nair, Mansi Mulay, Snehal Jaiswar, Trupti Pai, Gauri Deshpande, Nupur Karnik, Prarthna Shah, Aditi Arora, Archita Juneja, Sangeeta Desai, Omshree Shetty, Tanuja Shet","doi":"10.1016/j.jlb.2025.100319","DOIUrl":"10.1016/j.jlb.2025.100319","url":null,"abstract":"<p><strong>Introduction: </strong>Liquid biopsy testing has emerged as a pivotal tool in molecular characterization of solid malignancies. Circulating tumor DNA (ctDNA) analysis is quintessential in precision oncology for early detection, disease monitoring, prognosis, and theranostic purposes. This study summarizes ctDNA analysis performed on patients with advanced or metastatic solid tumors at tertiary cancer centers in India (2021-2024).</p><p><strong>Methods: </strong>ctDNA was isolated following standard pre-analytical protocols and quality control measures. Sequencing was performed using the Oncomine Precision Assay on Thermo Fisher platform and Custom Solid Tumor Panel (SOPHiA Genetics) on Illumina platforms. Variant annotation and clinical interpretation were performed as per ACMG and AMP Guidelines.</p><p><strong>Results: </strong>Out of 236 ctDNA samples, majority were lung malignancies (47 %), gastric cancers (43 %), head & neck cancers (2 %), other malignancies (8 %). A total of 250 clinically relevant genomic alterations were reported. On Illumina, 19.8 % of variants were classified as Tier I, 18.3 % Tier II, and 11.7 % as Tier III. Thermofisher platform identified Tier I alterations in 33 %, Tier II in 54 %, and Tier III in 11 % cases. In the GI cohort, <i>TP53</i> was most frequently mutated (51 %), followed by <i>KRAS</i> (25 %), <i>BRAF</i> (13 %), <i>PIK3CA</i> (13 %), and <i>CHEK2</i> (9 %). Among lung cancer patients, <i>EGFR</i> mutations (44 %), followed by <i>TP53</i> (43 %), <i>CDKN2A</i> (9 %), <i>PIK3CA</i> (9 %), and <i>BRAF</i> (6 %).Tissue-liquid biopsy concordance was observed in 36 of 96 cases for which baseline tissue NGS data was available. The mutational landscape derived from this cohort was compared with the MSKCC dataset for Asian and Western populations. The comparison revealed high concordance, clinical relevance, and reliability of liquid biopsy-based genomic profiling in diverse oncologic settings.</p><p><strong>Conclusion: </strong>Study underscores substantial increase in the adoption of liquid biopsy and the real-world utility of ctDNA-based NGS testing in solid tumors contributing to improved patient care management.</p>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"100319"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating biomarkers in HPV-associated oropharyngeal cancer: Clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance","authors":"Swati Kumari ,&nbsp;Sridhar Mishra ,&nbsp;Wahid Ali","doi":"10.1016/j.jlb.2025.100316","DOIUrl":"10.1016/j.jlb.2025.100316","url":null,"abstract":"<div><div>Oropharyngeal squamous cell carcinoma (OPSCC), particularly the HPV-associated subtype, represents a growing public health burden worldwide. While HPV-positive OPSCC carries a better prognosis, challenges persist in early detection, treatment response monitoring, and recurrence surveillance. Traditional tissue biopsy remains the diagnostic gold standard but is invasive, limited by sampling bias, and unsuitable for dynamic disease monitoring. This review synthesizes current evidence on the role of liquid biopsy including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating HPV DNA (ctHPV-DNA), circulating tumor cells (CTCs), exosomes, and microRNAs (miRNAs) in the diagnosis, prognostication, and surveillance of OPSCC. A literature review of human studies evaluating circulating biomarkers in OPSCC was performed. Eligible studies included prospective and retrospective investigations using liquid biopsy components for diagnostic, prognostic, or treatment-monitoring applications in HPV-positive or HPV-negative OPSCC. Among the circulating analytes, ctHPV-DNA has emerged as the most robust biomarker in HPV-positive OPSCC, offering high sensitivity and specificity for diagnosis and recurrence detection. Multiple studies support its utility in minimal residual disease (MRD) detection, often predicting recurrence months before clinical evidence. Saliva, plasma, and novel fluids like surgical lymphatic drainage have been evaluated as sampling sources. Additionally, ctDNA somatic mutations, gene methylation signatures, CTC counts, and exosomal miRNAs are being explored for their potential in personalized disease stratification and treatment monitoring. Liquid biopsy is a promising adjunct to tissue biopsy in OPSCC, particularly in HPV-driven disease. Its minimally invasive nature, dynamic tumor tracking capability, and expanding analytical platforms position it as a transformative tool in head and neck oncology. Standardization, assay optimization, and large-scale validation are required before routine clinical integration.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100316"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144739650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult","authors":"Michael Youssef ,&nbsp;Alexandra Larson ,&nbsp;Vindhya Udhane ,&nbsp;Kala F. Schilter ,&nbsp;Qian Nie ,&nbsp;Honey V. Reddi","doi":"10.1016/j.jlb.2025.100318","DOIUrl":"10.1016/j.jlb.2025.100318","url":null,"abstract":"<div><div>Adult brainstem gliomas are rare and present unique diagnostic and therapeutic challenges due to their critical location and limited biopsy feasibility. Molecular profiling of tumor-derived DNA (t-DNA) isolated from cerebrospinal fluid (CSF) is emerging as a minimally invasive alternative for characterizing these tumors and guiding targeted therapy. A 34-year-old woman with brainstem glioma was treated with a standard course of radiation and temozolomide (TMZ) and remained stable for several years. After surveillance imaging revealed disease progression and raised suspicion of IDH-mutant disease on MRI spectroscopy, molecular profiling of CSF was ordered. The Belay Summit test, a novel NGS-based liquid biopsy assay for central nervous system (CNS) tumors, identified variants in <em>IDH1</em> and <em>TP53</em> as well as loss of <em>CDKN2A</em>/<em>CDKN2B</em>. Based on these findings, the patient received a short course of radiation and was started on the <em>IDH</em> inhibitor vorasidenib. This case demonstrates the use of t-DNA from CSF for molecular profiling of adult brainstem glioma to identify actionable genomic alterations without surgical risk and allow patients to receive targeted therapy without tissue diagnosis.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100318"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of circulating lncRNAs HOTAIR, ANRIL, and MEG3 in oral squamous cell carcinoma and their correlation with clinicopathological features","authors":"Farhana Ikram ,&nbsp;Poorvi Mathur ,&nbsp;Pallavi Dubey ,&nbsp;Saloni Verma ,&nbsp;Sanjay Agarwal ,&nbsp;Shambhavi Tripathi","doi":"10.1016/j.jlb.2025.100315","DOIUrl":"10.1016/j.jlb.2025.100315","url":null,"abstract":"<div><h3>Background</h3><div>Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related morbidity and mortality worldwide, largely due to late-stage diagnosis and lack of reliable non-invasive biomarkers. Long non-coding RNAs (lncRNAs) such as HOTAIR, ANRIL, and MEG3 are emerging as potential liquid biopsy biomarkers in solid tumors. Current study evaluates the plasma expression levels of HOTAIR, ANRIL, and MEG3 in OSCC patients and assess their diagnostic potential and correlation with clinicopathological parameters.</div></div><div><h3>Material and methods</h3><div>In this case-control study, plasma samples were collected from 80 histologically confirmed treatment-naïve OSCC patients and 40 age- and sex-matched healthy controls. Quantitative real-time PCR (qRT-PCR) was performed to analyze lncRNA expression. Statistical analyses were conducted to assess differential expression, clinicopathological associations, and diagnostic performance via ROC curve analysis.</div></div><div><h3>Results</h3><div>Plasma HOTAIR and ANRIL were significantly upregulated (3.91- and 5.86-fold), while MEG3 was downregulated (0.12-fold) in OSCC compared to controls (p &lt; 0.001 for all). Elevated levels of HOTAIR and ANRIL were associated with poor histological grade, higher T and N stage, LVI, PNI, necrosis, and advanced stage (p = 0001). MEG3 levels decreased progressively with disease stage. Individually, each lncRNA achieved an AUC of 0.99 with high sensitivity and specificity. The three-lncRNA panel (HOTAIR + ANRIL + MEG3) yielded an AUC of 0.95, with 91.25 % sensitivity and 92.50 % specificity. MEG3 showed the best diagnostic performance for early-stage OSCC.</div></div><div><h3>Conclusion</h3><div>Plasma lncRNAs HOTAIR, ANRIL, and MEG3 show strong potential as non-invasive diagnostic biomarkers for OSCC, correlating with tumor aggressiveness and early disease detection. These findings support further validation in larger multicentric studies.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100315"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demonstrating the clinical utility of genomic profiling using cerebrospinal fluid to inform management of central nervous system tumors – a meta analysis of the literature","authors":"Sakshi Khurana ,&nbsp;Qian Nie ,&nbsp;Kala F. Schilter,&nbsp;Honey V. Reddi","doi":"10.1016/j.jlb.2025.100317","DOIUrl":"10.1016/j.jlb.2025.100317","url":null,"abstract":"<div><h3>Purpose</h3><div>Meta-analysis of literature was performed to gain an understanding of the performance of genomic profiling assays in cerebrospinal fluid (CSF) for the diagnosis and management of CNS cancers.</div></div><div><h3>Methods</h3><div>Using PRISMA methodology, PubMed was searched with the following search terms; “CSF and liquid biopsy” and “cerebrospinal fluid, liquid biopsy, mutations.” Key data fields such as DNA input, technologies used, biomarkers evaluated, types of CNS tumors, sensitivity and specificity, and performance outcomes were analyzed. Studies were excluded if they did not evaluate cancer, use CSF or molecular test methods, had &lt;10 patients, involved pediatric cases or were review articles.</div></div><div><h3>Results</h3><div>A total of 63 studies were included in the analysis with a majority using ctDNA (n = 38) and targeted NGS panels (n = 45) with both sensitivity and specificity being reported in 24 studies. Of the samples sequenced, 76 % of the primary cancers were gliomas with lung cancer making up 67 % of the metastatic cancers. The Belay Summit™ test performed significantly better in both primary and metastatic CNS cancers with 88 % and 95 % sensitivity respectively compared to studies that used NGS with 6 of the 24 demonstrating a median sensitivity of 47 ± 1.95 % for primary and 7 of 24 demonstrating a median sensitivity of 71 ± 0.76 % for metastatic cancers.</div></div><div><h3>Conclusions</h3><div>CSF does have potential to inform treatment and management of CNS tumors. For a CSF based molecular test to be highly sensitive and specific, key considerations include panel content, methodology used, the type of variants being evaluated and the inclusion of true negative controls.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100317"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144724534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy in breast cancer: Redefining precision medicine","authors":"Maria Luisa Schiavone ,&nbsp;Rosa Scarpitta ,&nbsp;Francesco Ravera ,&nbsp;Sara Bleve ,&nbsp;Carolina Reduzzi ,&nbsp;Federico Di Cocco ,&nbsp;Martina Dameri ,&nbsp;Gabriele Zoppoli ,&nbsp;Antonio Giuseppe Naccarato ,&nbsp;Pier Vitale Nuzzo ,&nbsp;Massimo Cristofanilli ,&nbsp;Giuseppe Nicolò Fanelli ,&nbsp;Cristian Scatena","doi":"10.1016/j.jlb.2025.100312","DOIUrl":"10.1016/j.jlb.2025.100312","url":null,"abstract":"<div><div>Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death among women worldwide. It represents a heterogeneous group of diseases with distinct morphological, immunophenotypic, and molecular profiles, which significantly impact clinical behavior and therapeutic response. Moreover, under treatment pressure, tumor cells may undergo molecular changes and phenotypic plasticity, leading to resistance and therapeutic failure. Although tissue biopsy remains the gold standard for diagnosis and molecular characterization, it has several limitations, including invasiveness, sampling bias, and the inability to dynamically capture tumor evolution over time. Hence, a non-invasive and repeatable approach capable of real-time monitoring is increasingly needed.</div><div>Liquid biopsy (LB), through the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), has emerged as a powerful tool to complement tissue biopsy. It allows for longitudinal assessment of tumor burden, detection of minimal residual disease, and identification of molecular alterations relevant to targeted therapies. Despite promising results, the integration of LB into clinical practice is still limited by methodological heterogeneity, standardization gaps, and regulatory issues. Nonetheless, LB represents a key advancement toward precision oncology and may become essential in the personalized management of BC patients.</div><div>In this review, we explore the current applications, benefits, and technical limitations of LB in different BC settings. We provide a comprehensive overview of the biological and clinical significance of CTCs and ctDNA, emphasizing their diagnostic, prognostic, and predictive roles. Finally, we present an updated summary of ongoing clinical trials that incorporate LB for clinical decision-making.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100312"},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy","authors":"Derek W. Brown ,&nbsp;Daokun Sun ,&nbsp;Alexander D. Fine ,&nbsp;Shai He ,&nbsp;Michael McDevitt ,&nbsp;Kerriann Pontbriand ,&nbsp;Eliana Polisecki ,&nbsp;Angela Kou ,&nbsp;Mingyue Li ,&nbsp;Shumeng Zhang ,&nbsp;Zheng Kuang ,&nbsp;David Fabrizio ,&nbsp;Russell W. Madison ,&nbsp;Jie He ,&nbsp;Zoe June Assaf ,&nbsp;Thomas Powles ,&nbsp;Christopher Sweeney ,&nbsp;David Gandara ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Lee A. Albacker ,&nbsp;Chang Xu","doi":"10.1016/j.jlb.2025.100311","DOIUrl":"10.1016/j.jlb.2025.100311","url":null,"abstract":"<div><h3>Purpose</h3><div>Genomic profiling of tumors by liquid biopsy (LBx) is a pragmatic alternative to profiling tissue. Despite recent methodologic advances, clonal hematopoiesis (CH) variants arising from hematopoietic stem cells may confound LBx results. Distinguishing the origin of variants detected by LBx will greatly enhance treatment decision-making for patients with cancer.</div></div><div><h3>Experimental design</h3><div>We sequenced DNA isolated from paired plasma and white blood cells (WBC) at equal depth to train (n = 1977) and validate (n = 658) Variant Origin Prediction (VOP), a machine learning algorithm that leverages fragmentomics to generate probabilities that a short variant (SV) detected by LBx is tumor-somatic, germline, or CH in origin. The algorithm's classifications were validated for accuracy using paired WBC DNA and for reproducibility using LBx replicates.</div></div><div><h3>Results</h3><div>We show that 68% of LBx detected at least one reportable variant of CH origin. Our fragmentomic-based algorithm differentiated reportable tumor and CH variants with high sensitivity, high positive predictive value (PPA &gt;93%, PPV &gt;91%), and high reproducibility (&gt;94%). Critically, VOP performs well for SVs with VAFs ≤1% (PPV &gt;90%), as well as in genes known to harbor both CH and tumor-somatic SVs, such as <em>TP53</em> (PPV &gt;88%). In a longitudinal cohort of 422 metastatic castration-resistant prostate cancer (mCRPC) cases, VOP accurately predicted baseline variant origins, and allowed separate tracking of tumor-somatic and CH variants, including newly detected variants, at subsequent timepoints.</div></div><div><h3>Conclusions</h3><div>VOP is a highly accurate and reproducible method to predict the origin of SVs detected in LBx without reliance on WBC sequencing. VOP can reduce inappropriate use of targeted therapies and their toxicities for patients with variants of CH origin and enables accurate tumor profiling and monitoring.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100311"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy: Current advancements in clinical practice for bladder cancer","authors":"Felice Crocetto ,&nbsp;Ugo Amicuzi ,&nbsp;Michele Musone ,&nbsp;Marco Magliocchetti ,&nbsp;Dario Di Lieto ,&nbsp;Simone Tammaro ,&nbsp;Antonio Luigi Pastore ,&nbsp;Andrea Fuschi ,&nbsp;Roberto Falabella ,&nbsp;Matteo Ferro ,&nbsp;Roberto Bianchi ,&nbsp;Marco Finati ,&nbsp;Gian Maria Busetto ,&nbsp;Giuseppe Lucarelli ,&nbsp;Francesco Del giudice ,&nbsp;Vincenzo Francesco Caputo ,&nbsp;Raffaele Balsamo ,&nbsp;Daniela Terracciano","doi":"10.1016/j.jlb.2025.100310","DOIUrl":"10.1016/j.jlb.2025.100310","url":null,"abstract":"<div><div>Bladder cancer is the ninth most common malignancy worldwide, with two clinically distinct forms: non-muscle-invasive disease, characterized by high recurrence and excellent long-term survival, and muscle-invasive disease, associated with poorer outcomes. Current surveillance—cystoscopy and urine cytology—offers high specificity but is invasive, costly, and insensitive to low-grade tumors, underscoring the need for reliable, non-invasive biomarkers. Liquid biopsy approaches in urine and blood have demonstrated promise for real-time assessment of tumor burden, molecular heterogeneity, and early recurrence. Circulating tumor DNA (ctDNA) assays detect tumor-derived genetic and epigenetic alterations, enabling dynamic monitoring of minimal residual disease and treatment response. Methylation-based tests and CpG-targeted sequencing in urine achieve high diagnostic accuracy, potentially reducing dependence on cystoscopy. Molecular classification of bladder tumors into luminal and basal subtypes has refined therapeutic strategies: FGFR inhibitors for luminal-papillary tumors, EGFR-targeted and chemotherapy approaches for basal/squamous cases, and immune-checkpoint inhibitors guided by immune-infiltration profiles. Integration of artificial intelligence with multi-omic liquid biopsy data further enhances predictive modeling for recurrence, treatment response, and minimal residual disease detection. Despite these advances, clinical implementation faces challenges including pre-analytical variability, lack of standardized assays, limited prospective validation, and unclear cost-effectiveness. Harmonized protocols, large multicenter trials, and health-economic evaluations are essential to translate liquid biopsy technologies into routine practice. Future integration with advanced imaging, tissue biopsy, and digital pathology—supported by multidisciplinary collaboration and formal guideline endorsement—holds the potential to personalize bladder cancer management, reduce invasive procedures, and improve patient outcomes.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100310"},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of circulating tumor cells in shaping the future of early-stage lung cancer treatment: a clinical point of view","authors":"Filippo Lococo ,&nbsp;Jessica Evangelista ,&nbsp;Carolina Sassorossi ,&nbsp;Elisa De Paolis ,&nbsp;Annalisa Campanella ,&nbsp;Maryam Heydary ,&nbsp;Yaqun Liu ,&nbsp;Davide Brechot ,&nbsp;Patrizia Paterlini ,&nbsp;Stefano Margaritora ,&nbsp;Angelo Minucci","doi":"10.1016/j.jlb.2025.100309","DOIUrl":"10.1016/j.jlb.2025.100309","url":null,"abstract":"","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100309"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-infiltrating lymphocytes in melanoma: diagnostic and prognostic implications from biopsy to circulation","authors":"Hussain Noorwali","doi":"10.1016/j.jlb.2025.100308","DOIUrl":"10.1016/j.jlb.2025.100308","url":null,"abstract":"<div><div>Melanoma is a highly aggressive skin cancer that arises from melanocytes and presents considerable clinical challenges due to its strong metastatic capacity and ability to evade the immune system. Tumor-infiltrating lymphocytes (TILs) reflect the host's immune activity within the tumor microenvironment and have gained recognition as important biomarkers for both diagnosis and prognosis in melanoma. A higher density of TILs—particularly CD8⁺ cytotoxic T cells—is associated with better overall survival and reduced risk of recurrence. Histopathological assessment of TILs, including classification systems like the Clark model, plays a key role in risk stratification, particularly in early-stage melanoma.</div><div>Meanwhile, peripheral blood T-cell profiling offers a non-invasive approach to assess systemic immune status. Circulating T-cell subsets and their expression of activation or exhaustion markers (e.g., PD-1, CTLA-4) reflect tumor immune dynamics and may serve as potential indicators of disease progression or prognosis.</div><div>Despite promising data, heterogeneity in TIL composition and peripheral immune profiles challenges consistent interpretation and clinical implementation. Future efforts should focus on standardizing TIL assessment, integrating tissue and blood immune markers, and leveraging computational tools to develop robust predictive models. This integrated immunological approach holds potential to refine melanoma prognosis and improve risk stratification.</div><div>This review aims to provide an updated and comprehensive overview of the diagnostic and prognostic significance of TILs and peripheral T-cell markers in melanoma. By synthesizing current evidence and addressing key limitations, it underscores the importance of immune profiling in advancing melanoma evaluation and guiding future research directions.</div></div>","PeriodicalId":101235,"journal":{"name":"The Journal of Liquid Biopsy","volume":"9 ","pages":"Article 100308"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}